Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Nippon Shinyaku Preparing for Clinical Studies of 5 Oligonucleotide Drugs to Cover 50% of DMD Patients: Pres.
November 8, 2018
- Takeda Launches Entyvio in Japan for Ulcerative Colitis
November 8, 2018
- Aspen Taking Over Anexate from Astellas
November 7, 2018
- Kyowa Kirin License Novel Blood Cancer Treatment from US Company
November 7, 2018
- EMA Accepts Quizartinib Application, with Accelerated Assessment Status: Daiichi Sankyo
November 7, 2018
- Balancing Act: All Eyes on Nesp Biosame Pricing before June 2019 Listing, Biosimilars to Follow in November
November 5, 2018
- Opdivo-Yervoy Combo Gets RCC Nod in Taiwan
November 5, 2018
- Kyowa Kirin to Start US PI Study on IDO Inhibitor-Bavencio Combo
November 5, 2018
- 8 Major Drug Makers See Flat Sales in 1st Half; Overseas Growth Continues to Compensate for Slumping Japan Revenue
November 5, 2018
- Pfizer Files Vyndaqel for Sakigake-Designated Transthyretin Amyloid Cardiomyopathy Indication in Japan
November 5, 2018
- JCR’s Fabrazyme Biosimilar to Enter NHI Price List as Early as November
November 5, 2018
- Takeda Unveils Estimated Net Debt, Goodwill Post Shire Integration
November 2, 2018
- Eisai, Merck to Start Lenvima Commercial Collaboration in Major Markets by March-End
November 2, 2018
- Eisai’s 1st Half Operating Profit Zooms 74% on Lenvima Boon
November 2, 2018
- Ono Plans to File Opdivo for 2nd-Line Esophageal Cancer by March-End
November 2, 2018
- Ono Racks Up 19% Revenue Rise on Positive Opdivo Sales
November 2, 2018
- Ribomic Launches PI/IIa Study of Anti-FGF2 Aptamer in US for AMD
November 2, 2018
- Astellas Investing 30 Billion Yen in R&D, Production Facilities Catering to Multiple Modalities
November 1, 2018
- Japan Needs New Pricing Model for Gene Therapies: Astellas Chief
November 1, 2018
- Astellas Sales Rep Number Now at 2,100; Redundancy Program Gets Underway
November 1, 2018
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…